Kimball Hall
Chief Executive Officer bei INNOCOLL HOLDINGS PLC
Vermögen: - $ am 31.03.2024
Profil
Kimball Hall is currently the Chief Executive Officer at Syntacoll Gmbh and the President & Chief Executive Officer at Innocoll Holdings Plc.
She is also serving as an Independent Director at Vera Therapeutics, Inc. Previously, she held the position of President, Chief Operating Officer & Director at Abzena Ltd.
and Senior Vice President at Genentech, Inc. From 2020 to 2023, she was the President & Chief Operating Officer at Abzena Holdings Us LLC.
Ms. Hall completed her undergraduate degree at the University of Washington.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
18.03.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Kimball Hall
Unternehmen | Position | Beginn |
---|---|---|
VERA THERAPEUTICS, INC. | Director/Board Member | 14.12.2021 |
INNOCOLL HOLDINGS PLC | Chief Executive Officer | 26.01.2023 |
Syntacoll Gmbh
Syntacoll Gmbh Pharmaceuticals: MajorHealth Technology Part of Innocoll Holdings Plc, Syntacoll GmbH is a German pharmaceutical company that develops and manufactures fully resorbable collagen-based implants. The private company is based in Saal an der Donau, Germany and was founded in 1992. The CEOs are Alexandra Dietrich and Kimball Hall. Syntacoll is the only development and production site of Innocoll, and their products are manufactured according to GMP and ISO 13485 standards. The company holds a manufacturing license for active substance-containing drugs based on collagen. Syntacoll's mission is to provide innovative medical and pharmaceutical products for patient care, and their vision is to be recognized as one of the leading providers of medical and pharmaceutical products worldwide. The company values integrity, inclusion, collaboration, and responsibility. | Chief Executive Officer | 26.01.2023 |
Ehemalige bekannte Positionen von Kimball Hall
Unternehmen | Position | Ende |
---|---|---|
Abzena Holdings Us LLC | President | 01.01.2023 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
ABZENA PLC | President | - |
Ausbildung von Kimball Hall
University of Washington | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
VERA THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Syntacoll Gmbh
Syntacoll Gmbh Pharmaceuticals: MajorHealth Technology Part of Innocoll Holdings Plc, Syntacoll GmbH is a German pharmaceutical company that develops and manufactures fully resorbable collagen-based implants. The private company is based in Saal an der Donau, Germany and was founded in 1992. The CEOs are Alexandra Dietrich and Kimball Hall. Syntacoll is the only development and production site of Innocoll, and their products are manufactured according to GMP and ISO 13485 standards. The company holds a manufacturing license for active substance-containing drugs based on collagen. Syntacoll's mission is to provide innovative medical and pharmaceutical products for patient care, and their vision is to be recognized as one of the leading providers of medical and pharmaceutical products worldwide. The company values integrity, inclusion, collaboration, and responsibility. | Health Technology |
Abzena Ltd.
Abzena Ltd. BiotechnologyHealth Technology Abzena Ltd. engages in the provision of proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It offers antibody discover and candidate screening, immunology and immunogenicity assessment, antibody and protein engineering, bio conjugation, custom synthesis of cytotoxic payloads, reagents, and other small molecules, manufacture of payload linkers, development of manufacturing cell lines, and manufacture of biopharmaceuticals. The company was founded by Sunil Shaunak in 2001 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Innocoll Holdings Plc
Innocoll Holdings Plc Pharmaceuticals: MajorHealth Technology Innocoll Holdings Plc operates as a pharmaceutical company. It focuses on the development and commercialization of pharmaceutical technologies to meet healthcare challenges. The firm's late-stage product pipeline is focused on addressing patient needs for postsurgical pain management. The company was founded in 1997 and is headquartered in Athlone, Ireland. | Health Technology |
Abzena Holdings Us LLC |